Repeat Antenatal Steroids Trial
Information source: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Complications, Pregnancy
Intervention: Betamethasone (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Official(s) and/or principal investigator(s): Ronald J Wapner, MD, Principal Investigator, Affiliation: MCP Hahnemann University Hospital
Summary
A course of steroids given to a mother who is in labor with a premature fetus will reduce
the risk of the premature infant dying or having serious complications. This trial will test
whether more than one course of antenatal steroids is more beneficial or risky to the infant
than a single course.
Clinical Details
Official title: A Randomized Placebo-Controlled Trial of Antenatal Corticosteroid Regimens
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: Composite outcome: including neonatal mortality/stillbirth, severe RDS, chronic lung disease, grade III/IV IVH, PVL
Secondary outcome: Neonatal morbidityMaternal morbidity Neonatal Growth parameters Infant neurological parameters
Detailed description:
After the NICHD Consensus Development Conference in 1994, the antenatal administration of
antenatal corticosteroids (betamethasone or dexamethasone) for prevention of death and the
serious morbidities associated with preterm birth has become an accepted standard in
American obstetric practice. Studies have shown that maximum beneficial effect occurs when
the fetus is delivered within 7 days of antenatal steroid administration. The efficacy and
safety of a single course of corticosteroids has been substantiated but it is unknown
whether repetitive dosing has similar efficacy or what the maternal, fetal and neonatal
risks are. Repeat courses of steroids are often administered. Two popular regimens exist
for the patient who remains undelivered more than one week after initial therapy but who
remains at risk for preterm birth. In one, steroids are repeated weekly until 34 weeks
gestation, while in the other, steroids are only given once.
This multicenter trial is testing the safety and efficacy of weekly administration of
antenatal steroids. Twenty four hundred women < 32. 0 weeks gestation who are at risk for
spontaneous preterm delivery and remain pregnant at least seven days after an initial course
of corticosteroids are being randomized to either weekly courses of masked study drug
(betamethasone or placebo) for 4 weeks or delivery, whichever comes first. Patients are
asked about side effects at the weekly visits and samples of maternal blood at randomization
and delivery are collected. Cord blood and placentas are also collected. Cranial
ultrasounds are done on all neonates. On a subgroup of patients, an adrenocorticotrophic
hormone (ACTH) stimulation test is being performed and an auditory brainstem response (ABR)
performed. All infants attend a follow-up visit at 18 to 22 months corrected age where
certified examiners, masked to study group assignment, collect physical and neurological
data. The Bayley Scales of Infant Development will also be administered. A subgroup of
infants will be seen at 36 months to administer the Intelligence scale from the McCarthy
Scales of Children's Abilities.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion criteria:
- Pregnant
- Gestational age > 23. 0 wks and < 31. 6 wks
- Singleton or twin pregnancy
- Intact membranes
- At-risk for spontaneous preterm delivery
- Received full course of corticosteroids within the previous 7 days
Exclusion criteria:
- Diagnosis of fetal lung maturity
- Chorioamnionitis
- Non-reassuring fetal testing
- Known major fetal anomaly
- Corticosteroid therapy, other than qualifying course
- Insulin dependent diabetes
- Active preterm labor at the time of randomization
- Delivery intended outside center
- Participation in any intervention study which influences neonatal morbidity or
mortality
- Previous participation in this trial
Locations and Contacts
University of Alabama, Birmingham, Alabama 35294, United States
University of Miami, Miami, Florida 33136, United States
Northwestern University-Prentice Hospital, Chicago, Illinois 60611, United States
University of Chicago, Chicago, Illinois 60637, United States
Dept of OB/GYN, Hutzel Hospital, Detroit, Michigan 48201, United States
Columbia University, New York City, New York 10032, United States
University of North Carolina, Chapel Hill, North Carolina 27599, United States
Forsyth Memorial Hospital, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27103, United States
University of Cincinnati, Cincinnati, Ohio 45267, United States
Case Western Reserve-Metrohealth, Cleveland, Ohio 44109, United States
Dept of OB/GYN, Ohio State University, Columbus, Ohio 43210, United States
MCP Hahnamann, Philadelphia, Pennsylvania 19102, United States
Dept of OB/GYN, Magee-Womens Hospital, Pittsburgh, Pennsylvania 15213, United States
Brown University -Women and Infants Hospital, Providence, Rhode Island 02095, United States
University of Tennessee, Memphis, Tennessee 38103, United States
Dept of OB/GYN, Southwestern Medical Center, University of Texas, Dallas, Texas 75235-9032, United States
University of Texas-Houston, Houston, Texas 77030, United States
University of Texas - San Antonio, San Antonio, Texas 78284, United States
University of Utah Medical Center, Salt Lake City, Utah 84132, United States
Additional Information
Click here for more information on NICHD clinical trials. Click here for more information on the NICHD MFMU Research Network.
Related publications: Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972 Oct;50(4):515-25. Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol. 1995 Jul;173(1):322-35. French NP, Hagan R, Evans SF, Godfrey M, Newnham JP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 1999 Jan;180(1 Pt 1):114-21. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA. 1995 Feb 1;273(5):413-8. Review. Gamsu HR, Mullinger BM, Donnai P, Dash CH. Antenatal administration of betamethasone to prevent respiratory distress syndrome in preterm infants: report of a UK multicentre trial. Br J Obstet Gynaecol. 1989 Apr;96(4):401-10. Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol. 1981 Oct 1;141(3):276-87. Wright LL. Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in very low birthweight infants. In: National Institute of Child Health and Development (US). Report on the Consensus Development Conference on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes; 1994 Feb 28-Mar 2; Bethesda, (MD): The Institute; 1994 Nov. P. 47-8. (NIH Publication; no. 95-3784).
Starting date: March 2000
Last updated: January 1, 2010
|